CN104093418A - 金黄色葡萄球菌抗原的含佐剂制剂 - Google Patents

金黄色葡萄球菌抗原的含佐剂制剂 Download PDF

Info

Publication number
CN104093418A
CN104093418A CN201280053918.1A CN201280053918A CN104093418A CN 104093418 A CN104093418 A CN 104093418A CN 201280053918 A CN201280053918 A CN 201280053918A CN 104093418 A CN104093418 A CN 104093418A
Authority
CN
China
Prior art keywords
seq
composition
antigen
tlr agonist
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280053918.1A
Other languages
English (en)
Chinese (zh)
Inventor
F·巴格诺利
B·宝德纳
S·布法力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104093418A publication Critical patent/CN104093418A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201280053918.1A 2011-09-01 2012-08-31 金黄色葡萄球菌抗原的含佐剂制剂 Pending CN104093418A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US61/530,162 2011-09-01
US201261607999P 2012-03-07 2012-03-07
US61/607,999 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
CN104093418A true CN104093418A (zh) 2014-10-08

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280053918.1A Pending CN104093418A (zh) 2011-09-01 2012-08-31 金黄色葡萄球菌抗原的含佐剂制剂

Country Status (14)

Country Link
US (1) US20140363461A1 (https=)
EP (1) EP2763695A1 (https=)
JP (1) JP2014525429A (https=)
KR (1) KR20140066212A (https=)
CN (1) CN104093418A (https=)
AU (1) AU2012300765A1 (https=)
BR (1) BR112014004782A2 (https=)
CA (1) CA2847204A1 (https=)
IL (1) IL231104A0 (https=)
IN (1) IN2014CN02152A (https=)
MX (1) MX2014002363A (https=)
RU (1) RU2014112343A (https=)
SG (1) SG11201400210RA (https=)
WO (1) WO2013030378A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646681A (zh) * 2016-01-21 2016-06-08 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011144566A (ru) * 2009-04-03 2013-05-10 Момента Фармасьютикалз, Инк. Контроль сополимерных композиций
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
AU2012214677B2 (en) * 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты
SI2822947T1 (sl) * 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Argininske soli TLR7 agonista
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
HUE044211T2 (hu) * 2012-08-31 2019-10-28 Glaxosmithkline Biologicals Sa Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
WO2005009378A2 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
KR20060065643A (ko) 2003-07-24 2006-06-14 머크 앤드 캄파니 인코포레이티드 스타필로코쿠스 아우레우스에 대한 방어 면역 반응을유도하는 폴리펩타이드
US20070134263A1 (en) 2004-02-18 2007-06-14 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
JPWO2007034881A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
US20080131457A1 (en) 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
US20080008682A1 (en) 2006-07-07 2008-01-10 Chong Lee S Modulators of toll-like receptor 7
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
AR065372A1 (es) 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
HRP20120895T1 (hr) 2007-05-08 2012-11-30 Astrazeneca Ab Imidazokinolini sa imuno-modulacijskim svojstvima
ES2359123T3 (es) 2007-08-03 2011-05-18 Pfizer Limited Imidazopiridinonas.
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
DK2276486T3 (da) 2008-03-24 2013-11-25 4Sc Discovery Gmbh Nye substituerede imidazo-quinoliner
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
CA2768485C (en) 2009-07-16 2018-12-04 Timothy Foster Treatment of staphylococci infections using recombinant fibrinogen binding protein clumping factor a
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
AU2011295853A1 (en) * 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты
JP2015510872A (ja) * 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
MX372965B (es) * 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
EP2822584A1 (en) * 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US20150203543A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
HUE044211T2 (hu) * 2012-08-31 2019-10-28 Glaxosmithkline Biologicals Sa Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
JP6324961B2 (ja) * 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
BR112015018014A2 (pt) * 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2011027222A2 (en) * 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646681A (zh) * 2016-01-21 2016-06-08 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用

Also Published As

Publication number Publication date
KR20140066212A (ko) 2014-05-30
CA2847204A1 (en) 2013-03-07
BR112014004782A2 (pt) 2017-03-21
MX2014002363A (es) 2014-04-14
EP2763695A1 (en) 2014-08-13
US20140363461A1 (en) 2014-12-11
AU2012300765A1 (en) 2014-03-13
SG11201400210RA (en) 2014-03-28
RU2014112343A (ru) 2015-10-10
JP2014525429A (ja) 2014-09-29
IL231104A0 (en) 2014-04-30
WO2013030378A1 (en) 2013-03-07
IN2014CN02152A (https=) 2015-09-04

Similar Documents

Publication Publication Date Title
CN104093418A (zh) 金黄色葡萄球菌抗原的含佐剂制剂
CN104159602B (zh) 加强疫苗的含佐剂制剂
JP4509554B2 (ja) アルミニウムアジュバントおよびヒスチジンを含むワクチン
CN1238696A (zh) 疫苗
AP431A (en) Influenza vaccine compositions.
KR102027429B1 (ko) 돌연변이 스태필로코쿠스 항원
CA3195971A1 (en) Neisseria meningitidis compositions and methods thereof
MX2015005306A (es) Nicotinamida como adyuvante.
JP2015521595A (ja) 血清群ｘ髄膜炎菌のためのワクチン
WO2020259633A1 (zh) 一种耐甲氧西林金黄色葡萄球菌人免疫球蛋白及其制备方法与应用
CN104582726A (zh) 狂犬病病毒免疫原的含佐剂制剂
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
KR20200053644A (ko) 보강제 제형 및 방법
CN101478987A (zh) 含有单克隆抗独特型抗ca-125抗体和铝的药物组合物
JP2022544407A (ja) 免疫原性組成物
CN100384476C (zh) 含有作为疫苗辅药的磷酸铁的疫苗组合物
AU2004235815A1 (en) Vaccinating against infectious diseases using proteosomes
KR20240147612A (ko) 향상된 효능을 갖는 알루미늄계 애주번트를 제조하는 방법
WO2024199359A1 (zh) 包含环二核苷酸分子的脂质体佐剂系统及其制备方法
HK40011275A (en) Polyvalent streptococcus pneumoniae vaccine composition
PL174077B1 (pl) Szczepionka do ochrony przed zakażeniem lub leczeniem zakażeń Hepatitis B i heterologicznych chorób, zawierająca antygen powierzchniowy Hepatitis B (HBsAg)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20141008

RJ01 Rejection of invention patent application after publication